569 related articles for article (PubMed ID: 15618294)
1. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease.
Wehkamp J; Schmid M; Fellermann K; Stange EF
J Leukoc Biol; 2005 Apr; 77(4):460-5. PubMed ID: 15618294
[TBL] [Abstract][Full Text] [Related]
2. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense.
Wehkamp J; Stange EF
Ann N Y Acad Sci; 2006 Aug; 1072():321-31. PubMed ID: 17057212
[TBL] [Abstract][Full Text] [Related]
3. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease.
Simms LA; Doecke JD; Walsh MD; Huang N; Fowler EV; Radford-Smith GL
Gut; 2008 Jul; 57(7):903-10. PubMed ID: 18305068
[TBL] [Abstract][Full Text] [Related]
4. Defensin-immunology in inflammatory bowel disease.
Wehkamp J; Stange EF; Fellermann K
Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S137-44. PubMed ID: 20117337
[TBL] [Abstract][Full Text] [Related]
5. Defensins and inflammation: the role of defensins in inflammatory bowel disease.
Ramasundara M; Leach ST; Lemberg DA; Day AS
J Gastroenterol Hepatol; 2009 Feb; 24(2):202-8. PubMed ID: 19215333
[TBL] [Abstract][Full Text] [Related]
6. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.
Wehkamp J; Harder J; Weichenthal M; Schwab M; Schäffeler E; Schlee M; Herrlinger KR; Stallmach A; Noack F; Fritz P; Schröder JM; Bevins CL; Fellermann K; Stange EF
Gut; 2004 Nov; 53(11):1658-64. PubMed ID: 15479689
[TBL] [Abstract][Full Text] [Related]
7. NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease.
Peyrin-Biroulet L; Chamaillard M
J Endotoxin Res; 2007; 13(3):135-9. PubMed ID: 17621555
[TBL] [Abstract][Full Text] [Related]
8. Defensins and other antimicrobial peptides in inflammatory bowel disease.
Wehkamp J; Schmid M; Stange EF
Curr Opin Gastroenterol; 2007 Jul; 23(4):370-8. PubMed ID: 17545771
[TBL] [Abstract][Full Text] [Related]
9. Host-microbe interaction: mechanisms of defensin deficiency in Crohn's disease.
Wang G; Stange EF; Wehkamp J
Expert Rev Anti Infect Ther; 2007 Dec; 5(6):1049-57. PubMed ID: 18039087
[TBL] [Abstract][Full Text] [Related]
10. Human defensins in Crohn's disease.
Wehkamp J; Fellermann K; Stange EF
Chem Immunol Allergy; 2005; 86():42-54. PubMed ID: 15976487
[TBL] [Abstract][Full Text] [Related]
11. Influence of standard treatment on ileal and colonic antimicrobial defensin expression in active Crohn's disease.
Kübler I; Koslowski MJ; Gersemann M; Fellermann K; Beisner J; Becker S; Rothfuss K; Herrlinger KR; Stange EF; Wehkamp J
Aliment Pharmacol Ther; 2009 Sep; 30(6):621-33. PubMed ID: 19549264
[TBL] [Abstract][Full Text] [Related]
12. Paneth cell antimicrobial peptides: topographical distribution and quantification in human gastrointestinal tissues.
Wehkamp J; Chu H; Shen B; Feathers RW; Kays RJ; Lee SK; Bevins CL
FEBS Lett; 2006 Oct; 580(22):5344-50. PubMed ID: 16989824
[TBL] [Abstract][Full Text] [Related]
13. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease.
Strober W; Asano N; Fuss I; Kitani A; Watanabe T
Immunol Rev; 2014 Jul; 260(1):249-60. PubMed ID: 24942694
[TBL] [Abstract][Full Text] [Related]
14. NOD2 mutation and mice: no Crohn's disease but many lessons to learn.
Wehkamp J; Stange EF
Trends Mol Med; 2005 Jul; 11(7):307-9. PubMed ID: 15955743
[TBL] [Abstract][Full Text] [Related]
15. [The role of defensins in the pathogenesis of chronic-inflammatory bowel disease].
Schmid M; Fellermann K; Wehkamp J; Herrlinger K; Stange EF
Z Gastroenterol; 2004 Apr; 42(4):333-8. PubMed ID: 15095125
[TBL] [Abstract][Full Text] [Related]
16. [Barrier- and autophagic functions of the intestinal epithelia: role of disturbances in the pathogenesis of Crohn's disease].
Lapis K
Orv Hetil; 2010 Oct; 151(40):1645-55. PubMed ID: 20860961
[TBL] [Abstract][Full Text] [Related]
17. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease.
Wehkamp J; Koslowski M; Wang G; Stange EF
Mucosal Immunol; 2008 Nov; 1 Suppl 1():S67-74. PubMed ID: 19079235
[TBL] [Abstract][Full Text] [Related]
18. Association of NOD2/CARD15 mutations on Crohn's disease phenotype in an Italian population.
Bianchi V; Maconi G; Ardizzone S; Colombo E; Ferrara E; Russo A; Tenchini ML; Porro GB
Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):217-23. PubMed ID: 17301648
[TBL] [Abstract][Full Text] [Related]
19. Functional characterisation of decoy receptor 3 in Crohn's disease.
Funke B; Autschbach F; Kim S; Lasitschka F; Strauch U; Rogler G; Gdynia G; Li L; Gretz N; Macher-Goeppinger S; Sido B; Schirmacher P; Meuer SC; Roth W
Gut; 2009 Apr; 58(4):483-91. PubMed ID: 19039087
[TBL] [Abstract][Full Text] [Related]
20. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn's disease.
D'Incà R; Annese V; di Leo V; Latiano A; Quaino V; Abazia C; Vettorato MG; Sturniolo GC
Aliment Pharmacol Ther; 2006 May; 23(10):1455-61. PubMed ID: 16669960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
